Genmab A/S - GMAB STOCK NEWS

Welcome to our dedicated page for Genmab A/S news (Ticker: GMAB), a resource for investors and traders seeking the latest updates and insights on Genmab A/S stock.

Genmab A/S (NASDAQ: GMAB) is a pioneering biotechnology company founded in February 1999 and headquartered in Copenhagen, Denmark. Established by Florian Schönharting, the company focuses on the development and commercialization of innovative antibody therapeutics for the treatment of cancer and other serious diseases.

Genmab's proprietary antibody technologies include DuoBody, HexaBody, DuoHexaBody, and HexElect. These cutting-edge platforms have enabled the creation of multiple high-impact drugs in partnership with leading pharmaceutical companies:

• Darzalex: Developed with Johnson & Johnson, this drug is a standard treatment for multiple myeloma.
• Tepezza: Partnered with Horizon, this medication targets thyroid eye disease.
• Kesimpta: Developed with Novartis, it treats relapsing multiple sclerosis.
• Rybrevant: Another collaboration with Johnson & Johnson, this drug addresses non-small cell lung cancer (NSCLC).
• Tivdak: In partnership with Seagen, Tivdak is used for the treatment of cervical cancer.
• Epkinly: Partnered with AbbVie, Epkinly targets diffuse large B-cell lymphoma.

In addition to these marketed products, Genmab has a robust pipeline of candidates targeting various oncologic indications. The company's focus on antibody therapeutics places it at the forefront of biotechnological innovation, continually seeking better outcomes for patients worldwide.

Genmab's financial health is bolstered by its successful alliances and product sales, positioning it strongly for future growth and development. Investors and stakeholders can stay informed about the latest updates and relevant information regarding Genmab's performance, events, and developments through regular news releases.